俄罗斯首次使用 siRNA 药物治疗心脏移植术后患者血脂异常的经验

M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov
{"title":"俄罗斯首次使用 siRNA 药物治疗心脏移植术后患者血脂异常的经验","authors":"M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov","doi":"10.15829/1560-4071-2024-5747","DOIUrl":null,"url":null,"abstract":"Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.","PeriodicalId":21389,"journal":{"name":"Russian Journal of Cardiology","volume":"52 11","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation\",\"authors\":\"M. Simonenko, A. Alieva, M. Y. Sitnikova, P. Fedotov\",\"doi\":\"10.15829/1560-4071-2024-5747\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.\",\"PeriodicalId\":21389,\"journal\":{\"name\":\"Russian Journal of Cardiology\",\"volume\":\"52 11\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Russian Journal of Cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15829/1560-4071-2024-5747\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Russian Journal of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15829/1560-4071-2024-5747","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

心脏移植(HT)后的患者罹患心血管疾病的风险非常高。无论性别、年龄和心力衰竭的起因如何,心脏受者的管理方案都包括启动降脂治疗(LLT)。考虑到药物相互作用和移植后并发症的风险,在移植人群中进行降脂治疗的可能性有限。本文介绍了俄罗斯首次使用 siRNA LLT 治疗实体器官移植受者血脂异常的经验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation
Patients after heart transplantation (HT) are at very high risk for cardiovascular disease. Protocols for the management of heart recipients include the initiation of lipid-lowering therapy (LLT), regardless of sex, age and origin of heart failure. Given drug interactions and the risk of post-transplant complications, the LLT possibilities are limited in the transplanted population. The paper presents first Russian experience of using siRNA LLT for the treatment of dyslipidemia in solid organ transplant recipients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Russian Journal of Cardiology
Russian Journal of Cardiology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
2.20
自引率
0.00%
发文量
185
审稿时长
1 months
期刊介绍: Russian Journal of Cardiology has been issued since 1996. The language of this publication is Russian, with tables of contents and abstracts of all articles presented in English as well. Editor-in-Chief: Prof. Eugene V.Shlyakhto, President of the Russian Society of Cardiology. The aim of the journal is both scientific and practical, also with referring to organizing matters of the Society. The best of all cardiologic research in Russia is submitted to the Journal. Moreover, it contains useful tips and clinical examples for practicing cardiologists. Journal is peer-reviewed, with multi-stage editing. The editorial board is presented by the leading cardiologists from different cities of Russia.
期刊最新文献
Mature neutrophils as a marker of hypoechoic carotid plaques and a predictor of polyvascular disease progression Oral anticoagulants versus vitamin K antagonists in the treatment of non-valvular atrial fibrillation in patients with stage 4-5 chronic kidney disease Myocardial infarction in persons aged ≥75 years: factors influencing inhospital mortality Comparative analysis of two multitask approaches to cognitive training in cardiac surgery patients Use of antiplatelet agents in patients after myocardial infarction followed up in Moscow outpatient clinics. Results of a non-interventional prospective study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1